Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease

被引:105
|
作者
Sookoian, Silvia [1 ,3 ,4 ]
Castano, Gustavo O. [3 ,4 ]
Burgueno, Adriana L. [2 ]
Soledad Rosselli, Maria [1 ,2 ]
Fernandez Gianotti, Tomas [2 ]
Mallardi, Pablo [5 ]
San Martino, Julio [5 ]
Jose Pirola, Carlos [2 ]
机构
[1] Univ Buenos Aires, Natl Council Sci & Technol Res CONICET, Inst Med Res A Lanari IDIM, Lab Clin & Mol Hepatol,Mol Genet & Biol Complex D, Buenos Aires, DF, Argentina
[2] Univ Buenos Aires, Natl Council Sci & Technol Res CONICET, Inst Med Res A Lanari IDIM, Lab Mol Genet & Biol Metab Syndrome,Mol Genet & B, Buenos Aires, DF, Argentina
[3] Res Council GCBA, Buenos Aires, DF, Argentina
[4] Hosp Abel Zubizarreta, Dept Med & Surg, Buenos Aires, DF, Argentina
[5] Hosp Diego Thompson, Dept Pathol, Buenos Aires, DF, Argentina
关键词
ICAM-1; PAI-1; sCD40L; CD40; Cardiovascular risk; Nonalcoholic steatohepatitis; NASH; NAFLD; Fatty liver; INTERCELLULAR-ADHESION MOLECULE-1; ALCOHOLIC HEPATITIS; METABOLIC SYNDROME; STEATOHEPATITIS; RISK; TISSUE; MEN; SEVERITY; SYSTEM; CELLS;
D O I
10.1016/j.atherosclerosis.2009.10.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: We evaluated circulating levels of biomarkers of atherosclerosis (soluble intercellular adhesion molecule: sICAM-1, plasminogen activator inhibitor: PAI-1 and soluble CD40 ligand: sCD40L) in patients with NAFLD proven through biopsy and control subjects, and correlated them with the histological disease severity. We further explored liver protein expression of ICAM-1, CD40 and PAI-1 in patients with different histological forms of NAFLD and control liver biopsies. Patients and methods: We included 215 individuals: 113 patients with NAFLD (simple steatosis n = 45 and NASH n = 68) and 102 control subjects. Circulating levels of the biomarkers were measured by ELISA. Liver expression of ICAM-1, CD40 and PAI-1 was assessed by immunohistochemistry using monoclonal antihuman antibodies. Results: Patients with NAFLD, in comparison with control subjects, showed significantly higher circulating levels of sICAM-1 (605.3 +/- 34.6 ng/ml vs. 356.5 +/- 24.6 ng/ml, p = 5.9 x 10(-6)), PAI-1 (22.8 +/- 1.7 ng/ml vs. 19.0 +/- 2.1 ng/ml, p = 0.0149) and sCD40L (1347.5 +/- 513.7 pg/ml vs. 804.5 +/- 396.1 pg/ml, p = 0.0229), results expressed as mean +/- SE. sICAM-1 was a strong predictor of histological severity of NAFLD, after adjusting for potential confounders. In addition, patients with NAFLD showed significantly higher liver staining scores for ICAM-1 and PAI-1 than control liver biopsies. ICAM-1 immunoreactivity in lobular inflammatory infiltrate showed high scores in NASH patients; a significant correlation was found between both the degree of liver steatosis and the severity of necroinflammatory activity and liver ICAM-1 expression. Conclusions: Our study shows that NAFLD is associated with elevated circulating levels and abnormal liver expression of molecular mediators of atherosclerosis. Additionally, ICAM-1 may be involved in liver damage and inflammation. (C)2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:585 / 591
页数:7
相关论文
共 50 条
  • [21] HEPATIC EXPRESSION AND SERUM LEVELS OF SYNDECAN 1 (CD138) IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE
    Yilmaz, Y.
    Eren, F.
    Colak, Y.
    Senates, E.
    Celikel, C. A.
    Imeryuz, N.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S537 - S537
  • [22] Circulating periostin in patients with nonalcoholic fatty liver disease
    Polyzos, Stergios A.
    Kountouras, Jannis
    Anastasilakis, Athanasios D.
    Papatheodorou, Athanasios
    Kokkoris, Panagiotis
    Terpos, Evangelos
    ENDOCRINE, 2017, 56 (02) : 438 - 441
  • [23] Circulating miRNAs associated with nonalcoholic fatty liver disease
    Atic, Amila Iriskic
    Thiele, Maja
    Munk, Alexander
    Dalgaard, Louise Torp
    AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2023, 324 (02): : C588 - C602
  • [24] Circulating periostin in patients with nonalcoholic fatty liver disease
    Stergios A. Polyzos
    Jannis Kountouras
    Athanasios D. Anastasilakis
    Athanasios Papatheodorou
    Panagiotis Kokkoris
    Evangelos Terpos
    Endocrine, 2017, 56 : 438 - 441
  • [25] Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease
    Polyzos, Stergios A.
    Anastasilakis, Athanasios D.
    Kountouras, Jannis
    Makras, Polyzois
    Papatheodorou, Athanasios
    Kokkoris, Panagiotis
    Sakellariou, Grigorios T.
    Terpos, Evangelos
    JOURNAL OF BONE AND MINERAL METABOLISM, 2016, 34 (04) : 447 - 456
  • [26] Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease
    Stergios A. Polyzos
    Athanasios D. Anastasilakis
    Jannis Kountouras
    Polyzois Makras
    Athanasios Papatheodorou
    Panagiotis Kokkoris
    Grigorios T. Sakellariou
    Evangelos Terpos
    Journal of Bone and Mineral Metabolism, 2016, 34 : 447 - 456
  • [27] The Role of Inflammatory Mediators in the Pathogenesis of Nonalcoholic Fatty Liver Disease
    Kim, Joon Sung
    PEDIATRIC GASTROENTEROLOGY HEPATOLOGY & NUTRITION, 2012, 15 (02) : 74 - 78
  • [28] Visfatin Levels in Nonalcoholic Fatty Liver Disease
    Akbal, Erdem
    Kocak, Erdem
    Tas, Adnan
    Yuksel, Enver
    Koklu, Seyfettin
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2012, 26 (02) : 115 - 119
  • [29] Adipocytokine Levels in Nonalcoholic Fatty Liver Disease
    Dogru, Teoman
    Ercin, Cemal Nuri
    Tapan, Serkan
    Kantarcioglu, Murat
    Kara, Muammer
    Baggi, Sait
    HEPATOLOGY, 2009, 50 (01) : 326 - 327
  • [30] The association of fatty pancreas with subclinical atherosclerosis in nonalcoholic fatty liver disease
    Ozturk, Kadir
    Dogan, Tolga
    Celikkanat, Serhat
    Ozen, Alptug
    Demirci, Hakan
    Kurt, Omer
    Turker, Turker
    Yilmaz, Yusuf
    Uygun, Ahmet
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 30 (04) : 411 - 417